Your browser doesn't support javascript.
loading
Modular Assembly of Allosteric MEK Inhibitor Structural Elements Unravels Potency and Feedback-Modulation Handles.
Hartung, Ingo V; Pühler, Florian; Neuhaus, Roland; Scholz, Arne; Siemeister, Gerhard; Geisler, Jens; Hillig, Roman C; von Ahsen, Oliver; Hitchcock, Marion.
Afiliación
  • Hartung IV; Medicinal Chemistry Berlin, Bayer HealthCare AG, 13353, Berlin, Germany. ingo.hartung@bayer.com.
  • Pühler F; Global Therapeutic Research Group Oncology, Bayer HealthCare AG, 13353, Berlin, Germany.
  • Neuhaus R; Research Pharmacokinetics, Bayer HealthCare AG, 13353, Berlin, Germany.
  • Scholz A; Global Therapeutic Research Group Oncology, Bayer HealthCare AG, 13353, Berlin, Germany.
  • Siemeister G; Global Therapeutic Research Group Oncology, Bayer HealthCare AG, 13353, Berlin, Germany.
  • Geisler J; Medicinal Chemistry Berlin, Bayer HealthCare AG, 13353, Berlin, Germany.
  • Hillig RC; Structural Biology, Bayer HealthCare AG, 13353, Berlin, Germany.
  • von Ahsen O; Global Biomarker Research, Bayer HealthCare AG, 13353, Berlin, Germany.
  • Hitchcock M; Medicinal Chemistry Berlin, Bayer HealthCare AG, 13353, Berlin, Germany. marion.hitchcock@bayer.com.
ChemMedChem ; 10(12): 2004-13, 2015 Dec.
Article en En | MEDLINE | ID: mdl-26541480
ABSTRACT
Having recently identified a so-far unexplored area adjacent to the known binding site of allosteric mitogen-activated protein kinase kinase (MEK) inhibitors, we now report an extension of these studies by combining our new side chains with different MEK inhibitor cores in a modular manner. Replacement of the amide headgroup with inverse sulfonamides resulted in the identification of new MEK inhibitors with at least 10-fold higher cellular potency against K-Ras-mutated tumor cells. A selected inhibitor from this new series retained the favorable pharmacokinetic profile of its predecessor in rodent and non-rodent species and displayed significant in vivo efficacy at once-daily oral doses of 0.25-1 mg kg(-1) in a K-Ras-mutated xenograft model. The brain penetration potential of this analogue was significantly attenuated relative to PD325901. In a second series, the central fluorophenyl core was replaced by a pyridine moiety which gave rise to a similar boost in cellular potency. Most notably, analogues from this second series do not show MEK feedback phosphorylation in K-Ras-mutated A549 cells. Our results complement recent reports on the structural intricacies of MEK-Raf feedback interactions.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: MAP Quinasa Quinasa 1 / Inhibidores de Proteínas Quinasas Idioma: En Revista: ChemMedChem Asunto de la revista: FARMACOLOGIA / QUIMICA Año: 2015 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: MAP Quinasa Quinasa 1 / Inhibidores de Proteínas Quinasas Idioma: En Revista: ChemMedChem Asunto de la revista: FARMACOLOGIA / QUIMICA Año: 2015 Tipo del documento: Article